💡 Quick answer
The landmark clinical studies, treatment history and latest research for Low-level laser (LLLT) — fact-checked and sourced.
Key termsMinoxidil
Research & evidence
How treatment evolved
1967Endre Mester (Hungary), using a low-power ruby laser (694 nm) on mice, serendipitously observed faster hair regrowth and wound healing at treated sites — the founding observation of 'laser biostimulation,' later termed photobiomodulation / low-level laser therapy.
2007The HairMax LaserComb (655 nm) received the first-ever FDA 510(k) clearance for an at-home LLLT device for male androgenetic alopecia (cleared as substantially equivalent to a predicate device, not via the drug-approval pathway).
2011FDA clearance of the HairMax LaserComb was expanded to include female pattern hair loss, broadening the cleared indication to both sexes.
2014Publication of the largest set of sham-controlled, double-blind RCTs of an LLLT comb device (Jimenez et al., Am J Clin Dermatol), establishing the core regulatory/clinical evidence base for the modality in both men and women.
2019First comprehensive systematic review and meta-analysis pooling LLLT-vs-sham RCTs for AGA (Liu et al., Lasers in Medical Science) confirmed a statistically significant increase in hair density but flagged substantial between-trial heterogeneity, framing the modern consensus that evidence is positive but low-to-moderate quality.
Key clinical studies
Jimenez et al., 20142014
269 subjects (128 men, 141 women) across multiple sham-controlled, double-blind RCTs (7-, 9-, and 12-beam HairMax LaserComb devices, ~655 nm), 26 weeks
At 26 weeks, lasercomb-treated arms gained roughly +18 to +26 terminal hairs/cm2 versus only +1.6 to +9.4/cm2 in sham arms; differences were statistically significant (p<0.0001 for female 9- and 12-beam arms; male arms p=0.0017 to p=0.0249).
American Journal of Clinical Dermatology
Lanzafame et al., 2013 (men) & 2014 (women)2013
Males trial recruited 44 (41 commonly cited as completed/analyzed); females trial enrolled 47, 42 completed (24 active, 18 sham). Otherwise as claimed.
Active treatment increased hair counts by about 35% over sham in men (p=0.003) and about 37% over sham in women — pivotal trials supporting FDA clearance of helmet/cap-style LLLT devices.
Lasers in Surgery and Medicine
Liu et al., 2019 (systematic review & meta-analysis)2019
Meta-analysis of 8 studies comprising 11 double-blind RCTs of LLLT versus sham for androgenetic alopecia
LLLT significantly increased hair density versus sham, with a pooled standardized mean difference of 1.316 (95% CI 0.993-1.639); benefit was seen in both sexes and comb- and helmet-type devices, but the authors stressed the analysis was limited by heterogeneity of the included trials.
Lasers in Medical Science
Latest research: Recent work (2023-2026) has shifted from LLLT monotherapy toward combination regimens, with several 2024-2025 systematic reviews and meta-analyses reporting that LLLT plus topical minoxidil outperforms minoxidil alone with a comparable safety profile, while continuing to flag a limited, heterogeneous, and often industry-linked evidence base that calls for larger, standardized RCTs.
Summaries reflect published, peer-reviewed research and are not medical advice. See the linked sources for details.
Explore more
Self-check →Treatments →Transplant →Women →New →Hair Loss Causes →Hair-Loss Glossary →Hair-Loss Questions & Answers →Hair-Loss Ingredient Evidence Ratings →Hair Transplant Cost by City →Research →Browse all →
Not medical advice. General education only; it does not replace diagnosis or treatment by a licensed professional. Consult a board-certified dermatologist before starting, stopping or changing any treatment.
⚠️ When to see a doctor — don’t self-treat
- Sudden patchy or circular bald spots
- Redness, scaling, pus, pain or itch (possible scarring alopecia — treat urgently)
- Broken hairs or rapid loss
- Loss with body-wide signs (weight loss, fatigue, cycle changes, acne, extra hair)
- Loss right after a new medication
- Any hair loss in a child